Art. -Nr.: HY-10992

AZD-7762

Name: AZD-7762
Brand: MedChemExpress
SKU: HY-10992
Price: 92.00 USD
Availability: InStock
Rating: 5 (26 reviews)

26 Cited Publications

Kundenbewertung

Based on 26 publication(s) in Google Scholar

AZD-7762 is a potent ATP-competitive checkpoint kinase (Chk) inhibitor in with an IC₅₀ of 5 nM for Chk1.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.60%
CAS. Nr.: 860352-01-8
Formel: C₁₇H₁₉FN₄O₂S
Molecular Weight:362.42

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

AZD-7762 Chemical Structure

CAS. Nr.: 860352-01-8

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (26)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

AZD-7762 is a potent ATP-competitive checkpoint kinase (Chk) inhibitor in with an IC₅₀ of 5 nM for Chk1.

IC₅₀ & Target^[1]

Chk1

5 nM (IC₅₀)

Chk2

5 nM (IC₅₀)

Alle Checkpoint Kinase (Chk) Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
HEK293	GI₅₀	0.236 μM Compound: AZD7762	Antiproliferative activity against human HEK293 cells after 72 hrs by MTS assay Antiproliferative activity against human HEK293 cells after 72 hrs by MTS assay	[PMID: 29684894]
HT-29	EC₅₀	0.01 μM Compound: 4, AZD-7762	Inhibition of CHK1 in human HT29 cells assessed as abrogation of camptothecin induced check point Inhibition of CHK1 in human HT29 cells assessed as abrogation of camptothecin induced check point	[PMID: 22551018]
HT-29	EC₅₀	0.28 μM Compound: 4, AZD-7762	Inhibition of CHK1 in human HT29 cells assessed as check point abrogation Inhibition of CHK1 in human HT29 cells assessed as check point abrogation	[PMID: 22551018]
HT-29	EC₅₀	0.62 μM Compound: AZD7762	Induction of cell cycle arrest in human HT-29 cells incubated for 20 hrs by phH3 staining based analysis Induction of cell cycle arrest in human HT-29 cells incubated for 20 hrs by phH3 staining based analysis	[PMID: 18790776]
HT-29	EC₅₀	10 nM Compound: AZD7762	Inhibition of camptothecin induced DNA damage in human HT-29 cells assessed as G2 checkpoint abrogation measured after 20 hrs presence of nocodazole by pHH3 staining based analysis Inhibition of camptothecin induced DNA damage in human HT-29 cells assessed as G2 checkpoint abrogation measured after 20 hrs presence of nocodazole by pHH3 staining based analysis	[PMID: 18790776]
HT-29	GI₅₀	0.167 μM Compound: AZD7762	Antiproliferative activity against human HT-29 cells after 72 hrs by MTS assay Antiproliferative activity against human HT-29 cells after 72 hrs by MTS assay	[PMID: 29684894]
MDA-MB-231	GI₅₀	0.15 μM Compound: AZD7762	Growth inhibition of human MDA-MB-231 cells expressing p53 mutant assessed as reduction in cell growth incubated for 48 hrs in presence of topotecan Growth inhibition of human MDA-MB-231 cells expressing p53 mutant assessed as reduction in cell growth incubated for 48 hrs in presence of topotecan	[PMID: 18790776]
SW-620	GI₅₀	1.08 nM Compound: AZD7762	Growth inhibition of human SW620 cells expressing p53 mutant assessed as reduction in cell growth incubated for 48 hrs in presence of gemcitabine Growth inhibition of human SW620 cells expressing p53 mutant assessed as reduction in cell growth incubated for 48 hrs in presence of gemcitabine	[PMID: 18790776]

In Vitro

AZD-7762 (AZD7762) is an equally potent inhibitor of Chk1 and Chk2 in vitro. AZD-7762 potently inhibits Chk1 and Chk2, abrogates DNA damage-induced S and G₂ checkpoints, enhances the efficacy of NSC 613327 and SKF 104864A, and modulates downstream checkpoint pathway proteins. AZD-7762 potently inhibits Chk1 phosphorylation of a cdc25C peptide with an IC₅₀ of 5 nM as measured by a scintillation proximity assay. The K_i for AZD-7762 is determined to be 3.6 nM. Kinetic characterization suggests that AZD-7762 binds in the ATP-binding site of Chk1 and is thought to compete directly for ATP binding in a reversible manner. AZD-7762 is shown to abrogate the G₂ arrest induced by Camptothecin with an average EC₅₀ of 10 nM (n=12) and maximal abrogation in the range of 100 nM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

In the rat H460-DNp53 xenograft study, AZD-7762 (AZD7762) potentiates the antitumor activity of NSC 613327 in a dose-dependent manner by a decrease in %T/C with increasing dose (48% and 32%, 10 and 20 mg/kg AZD-7762, respectively). In the mouse xenograft study in combination with CPT-11, SW620 established tumors are treated with vehicle, CPT-11 alone, AZD-7762 alone, or AZD-7762 in combination with CPT-11. AZD-7762 dosed alone shows insignificant antitumor activity, whereas CPT-11 alone displays striking and significant activity (%T/C with increasing dose is 9 and 1, respectively ). In combination with AZD-7762, %T/C increases significantly to -66% and -67%, respectively^[1]. AZD7762 combination with CX-5461 induces cancer cell death of Tp53-null (Tp53^-/-) Eμ-Myc lymphoma cells in vitro and in vivo^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 860352-01-8
Appearance Solid
Molecular Weight 362.42
Formel C₁₇H₁₉FN₄O₂S
Color White to yellow
SMILES

O=C(N[C@@H]1CNCCC1)C2=C(C=C(S2)C3=CC=CC(F)=C3)NC(N)=O
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (26)

All In Vivo Efficacy StudyIFOthersWBHistological Imaging/Staining

Sort by:

Journal Impact Factor

Cell

Extrachromosomal DNA replication and maintenance couple with DNA damage pathway in tumors. [Abstract]

2025 Jun 26;188(13):3405-3421.e27. PMID: 40300601
Nat Nanotechnol

Therapeutically reprogrammed nutrient signalling enhances nanoparticulate albumin bound drug uptake and efficacy in KRAS-mutant cancer. [Abstract]

2021 Jul;16(7):830-839. PMID: 33958764
Cell Metab

Imatinib and methazolamide ameliorate COVID-19-induced metabolic complications via elevating ACE2 enzymatic activity and inhibiting viral entry. [Abstract]

2022 Mar 1;34(3):424-440.e7. PMID: 35150639
Nat Immunol

A method for predicting drugs that can boost the efficacy of immune checkpoint blockade. [Abstract]

2024 Apr;25(4):659-670. PMID: 38499799

AZD-7762 purchased from MedChemExpress. Usage Cited in: Nat Immunol. 2024 Apr;25(4):659-670. [Abstract]

AZD-7762 (25 mg/kg). Mean tumor growth curve of LLC tumor-bearing mice.
Nat Commun

Structure of the DDB1-AMBRA1 E3 ligase receptor complex linked to cell cycle regulation. [Abstract]

2023 Nov 22;14(1):7631. PMID: 37993427

AZD-7762 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2023 Nov 22;14(1):7631. [Abstract]

Pan-γH2AX-positive cells in AMBRA1 knockdown, AMBRA1 WT and single mutant overexpression U2OS cells. Cells were treated with DMSO or 100 nM AZD7762 for 24 h, then harvested for immunofluorescence.
Exp Hematol Oncol

Combinatorial functionomics identifies HDAC6-dependent molecular vulnerability of radioresistant head and neck cancer. [Abstract]

2025 Jan 12;14(1):5. PMID: 39800760

AZD-7762 purchased from MedChemExpress. Usage Cited in: Exp Hematol Oncol. 2025 Jan 12;14(1):5. [Abstract]

Representative immunoblots of cleaved caspase 3 and its downstream target cleaved PARP upon treatment with Pano and/or AZD7762 (150 nM), for 48 h.
Sci Transl Med

Small-molecule screen reveals synergy of cell cycle checkpoint kinase inhibitors with DNA-damaging chemotherapies in medulloblastoma. [Abstract]

2021 Jan 20;13(577):eaba7401. PMID: 33472956

AZD-7762 purchased from MedChemExpress. Usage Cited in: Sci Transl Med. 2021 Jan 20;13(577):eaba7401. [Abstract]

Results of the interaction between four CHK inhibitors (AZD-7762) and the MB chemotherapy drug (4-HPC).

AZD-7762 purchased from MedChemExpress. Usage Cited in: Sci Transl Med. 2021 Jan 20;13(577):eaba7401. [Abstract]

AZD-7762 (30 mg/kg). Representative immunohistochemical (IHC) images of γH2AX or phosphorylated (p) CDC2 Tyr 15 in medulloblastoma (MB) tissues from Smo mice.
Sci Transl Med

PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. [Abstract]

2018 Jul 18;10(450):eaaq1093. PMID: 30021885
Arch Toxicol

SIRT3-dependent mitochondrial redox homeostasis mitigates CHK1 inhibition combined with gemcitabine treatment induced cardiotoxicity in hiPSC-CMs and mice. [Abstract]

2023 Dec;97(12):3209-3226. PMID: 37798514
Acta Pharmacol Sin

Activation of unfolded protein response overcomes Ibrutinib resistance in diffuse large B-cell lymphoma. [Abstract]

2021 May;42(5):814-823. PMID: 32855532
Cell Rep

Cell stretching activates an ATM mechano-transduction pathway that remodels cytoskeleton and chromatin. [Abstract]

2023 Dec 11;42(12):113555. PMID: 38088930
Cancer Cell Int

Construction of a prognostic model with histone modification-related genes and identification of potential drugs in pancreatic cancer. [Abstract]

2021 Jun 5;21(1):291. PMID: 34090418
Mol Cancer Ther

2026 Jul 15:10.1158/1535-7163.MCT-26-0182. PMID: 42456172
Int Immunopharmacol

CHK1 inhibition by prexasertib sensitizes cisplatin-resistant malignant tumor cells via checkpoint abrogation and STAT1-driven PD-L1 upregulation. [Abstract]

2026 Feb 15:171:116126. PMID: 41477994
Inflammation

SHP2 Targets ITK Downstream of PD-1 to Inhibit T Cell Function. [Abstract]

2021 Aug;44(4):1529-1539. PMID: 33624224
Int J Cancer

Enhanced pharmacological activities of AKR1C3-activated prodrug AST-3424 in cancer cells with defective DNA repair. [Abstract]

2025 Jan 15;156(2):417-430. PMID: 39243400
Eur J Cell Biol

MDC1 promotes nuclear localization of Beclin-1 and supports its role in ATM pathway in response to oxidative stress. [Abstract]

2026 Apr 17;105(3):151540. PMID: 42013721
Immunol Lett

VRK2 inhibition synergizes with PD-1 blockade to improve T cell responses. [Abstract]

2021 May:233:42-47. PMID: 33741379
FEBS Lett

Fbxo6 confers drug-sensitization to cisplatin via inhibiting the activation of Chk1 in non-small cell lung cancer. [Abstract]

2019 Jul;593(14):1827-1836. PMID: 31140586
PLoS One

ERK-mediated TIMELESS expression suppresses G2/M arrest in colon cancer cells. [Abstract]

2019 Jan 10;14(1):e0209224. PMID: 30629587
PLoS One

DNA Double-Strand Breaks Induce the Nuclear Actin Filaments Formation in Cumulus-Enclosed Oocytes but Not in Denuded Oocytes. [Abstract]

2017 Jan 18;12(1):e0170308. PMID: 28099474

AZD-7762 purchased from MedChemExpress. Usage Cited in: PLoS One. 2017 Jan 18;12(1):e0170308. [Abstract]

Inhibition of nuclear actin filament formation by Chek1/2 inhibitor, AZD7762 (AZD). No nuclear actin filament formation is observed upon treatment of CEOs with AZD alone.
Anticancer Drugs

AZD7762 induces CRBN dependent BAG3 degradation through ubiquitin-proteasome pathway. [Abstract]

2024 Jan 1;35(1):46-54. PMID: 37449977
Data Brief

Data on the identification of VRK2 as a mediator of PD-1 function. [Abstract]

2021 May 21:37:107168. PMID: 34113705
Research Square Preprint

2024 Nov 06.
Research Square Print

September 27th, 2022.
Oncotarget

Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling. [Abstract]

2016 Aug 2;7(31):49800-49818. PMID: 27391441

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (275.92 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.7592 mL

13.7961 mL

27.5922 mL

5 mM

0.5518 mL

2.7592 mL

5.5184 mL

10 mM

0.2759 mL

1.3796 mL

2.7592 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (6.90 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (6.90 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (6.90 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% HP-β-CD in Saline water

Solubility: 10 mg/mL (27.59 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

Cell Assay^[1]

SW620 (5.5×10³ per well) or MDA-MB-231 (5×10³ per well) cells are seeded in 96-well plates and incubated overnight. Cells are dosed for 24 h with a 9-point titration of NSC 613327 ranging from 0.01 to 100 nM with or without a constant dose of AZD-7762 (300 nM). Control wells are dosed with vehicle alone (0.1% DMSO) or 300 nM AZD-7762. After 24 h, medium is removed and AZD-7762 alone is added back to the wells treated previously with AZD-7762 for an additional 24 h. Cells are then incubated in drug-free medium for an additional 72 h. The effect on cell proliferation is determined by MTS assay^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[1]^[2]

Mice and Rats^[1]
Male NCr mice and male rnu rats are used. For xenograft models in mice, tumor cells are harvested, pelleted by centrifugation for 5 min, and resuspended in sterile PBS. Cells (3×10³-6×10⁶) are implanted s.c. into the right flank of the mice in a volume of 0.1 to 0.2 mL using a 25-gauge needle. Tumors are allowed to grow to the designated size of 100 to 200 mm³ before the administration of compound. For xenograft models in rats, Cells are harvested, pelleted by centrifugation for 5 min, and resuspended in 50% sterile PBS and 50% Matrigel. Rats receive a 5 Gy whole-body radiation dose 5 days before cell implantation to improve tumor growth. H460-DNp53 cells (1×10⁷) are implanted s.c., into the right flank of the rats in a volume of 0.2 mL using a 25-gauge needle. Tumors are allowed to grow to the designated size of 100 to 200 mm³ before the administration of AZD-7762. AZD-7762 (10 and 20 mg/kg) is administered by i.v. injection via the tail vein. Cyclic schedules are used and treatment ranged from three to five cycles. Each cycle includes administration of a standard agent (NSC 613327 or CPT-11) every 3 days follow by delivery of AZD-7762. Tumor volumes are measured with electronic calipers and calculated.
Mice ^[2]
C57Bl/6 mice are intravenously injected with 2×10⁵ Eμ-Myc B-lymphoma cells in PBS and treated with pharmacological inhibitors from 8 days post-injection. Treatment of mice is continued until an ethical end-point is reached; hunched posture, ruffled fur, enlarged lymph nodes, laboured breathing, weight loss greater than 20% of start body weight and limited mobility or paralysis. AZD7762 is delivered intraperitoneally in 10.3% -hydroxypropyl-β-cyclodextrin in 0.9% saline at 20 mg/kg daily on weekdays.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (282 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Zabludoff SD, et al. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol Cancer Ther. 2008 Sep;7(9):2955-66. [Content Brief]

[2]. Quin J, et al. Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling. Oncotarget. 2016 Aug 2;7(31):49800-49818. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.7592 mL	13.7961 mL	27.5922 mL	68.9804 mL
	5 mM	0.5518 mL	2.7592 mL	5.5184 mL	13.7961 mL
	10 mM	0.2759 mL	1.3796 mL	2.7592 mL	6.8980 mL
	15 mM	0.1839 mL	0.9197 mL	1.8395 mL	4.5987 mL
	20 mM	0.1380 mL	0.6898 mL	1.3796 mL	3.4490 mL
	25 mM	0.1104 mL	0.5518 mL	1.1037 mL	2.7592 mL
	30 mM	0.0920 mL	0.4599 mL	0.9197 mL	2.2993 mL
	40 mM	0.0690 mL	0.3449 mL	0.6898 mL	1.7245 mL
	50 mM	0.0552 mL	0.2759 mL	0.5518 mL	1.3796 mL
	60 mM	0.0460 mL	0.2299 mL	0.4599 mL	1.1497 mL
	80 mM	0.0345 mL	0.1725 mL	0.3449 mL	0.8623 mL
	100 mM	0.0276 mL	0.1380 mL	0.2759 mL	0.6898 mL

Bioz

Keywords

AZD-7762

26 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

AZD-7762

Rabusertib

SCH900776

Prexasertib

PF 477736

Adavosertib

BML-277

CCT245737

CHIR-124

Ceralasertib

KU-55933

GDC-0575

Olaparib

Publications Citing Use of MedChemExpress (MCE) AZD-7762

Alle Checkpoint Kinase (Chk) Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (26)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Bioz

AZD-7762

Rabusertib

SCH900776

Prexasertib

PF 477736

Adavosertib

BML-277

CCT245737

CHIR-124

Ceralasertib

KU-55933

GDC-0575

Olaparib

Publications Citing Use of MedChemExpress (MCE) AZD-7762

Alle Checkpoint Kinase (Chk) Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (26)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

AZD-7762 Related Classifications

HY-10992 Related Classifications

Bioz